Tumoral necrosis factor α plays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab) has turned into the most important tool in the management of a variety of disorders, such as rheumatoid arthritis, spondyloarthropatties, inflammatory bowel disease, and psoriasis. Nonetheless, theoretically, some other autoimmune disorders may benefit from these agents. Our aim is to review these off-label uses of anti-TNF blockers in three common conditions: Behçet's disease, sarcoidosis, and noninfectious uveitis. Due to the insufficient number of adequate clinical trials and consequently to their lower prevalence compared to other immune disorders, this review is mainly based on case reports and case series.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747407 | PMC |
| http://dx.doi.org/10.1155/2013/286857 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ustekinumab is an effective therapy for adult Crohn's disease (CD), but data in paediatric CD patients are scarce. The aim of the study was to describe the real-life effectiveness and safety of ustekinumab in paediatric CD. This is a multicentre review of children with Crohn's disease treated with ustekinumab.
View Article and Find Full Text PDFPrecise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA.
BMJ Open
March 2024
Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, Ohio, USA.
Article Synopsis
- The only currently approved therapy for moderate to severe Crohn's disease in children is anti-TNF biologics, making it essential to enhance treatment strategies for improved outcomes.
- Early optimization of anti-TNF dosing, guided by therapeutic monitoring, has shown better rates of sustained remission and drug effectiveness for these patients.
- A clinical trial will compare results from precision dosing of infliximab against conventional dosing, with the aim of assessing deep remission rates in young patients with Crohn's disease.
Adverse events of biological agents in pediatric rheumatologic diseases.
Postgrad Med
March 2024
Department of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, Turkey.
Objectives: To evaluate adverse events (AEs) in pediatric patients with rheumatologic diseases being treated with approved or off-label biologic agents (BAs).
Methods: This observational, retrospective, multicenter study was conducted from 2010 to 2022 in patients under 18 years of age with rheumatic diseases who were receiving interleukin-1 antibodies (Anti-IL1), interleukin-6 antibodies (Anti-IL6), and tumor necrosis factor alpha inhibitors (anti-TNF). Efficacy, AEs, and timing of AEs were collected from electronic medical records.
Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm.
Expert Rev Clin Immunol
May 2024
Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Article Synopsis
- * Approved treatments for HS include two biologics, adalimumab and secukinumab, which provide moderate relief, while research into new drugs targeting different pathways is rapidly advancing, especially those focused on IL-17 and the JAK/STAT pathways.
- * The article suggests a tailored treatment approach considering patient-specific factors and comorbidities, aiming for better management of HS symptoms through personalized combinations of biologics and other therapies.
Managing pediatric Crohn's disease: recent insights.
Expert Rev Gastroenterol Hepatol
November 2023
Division of Digestive Diseases, Hepatology, and Nutrition, Connecticut Children's Medical Center, Hartford, CT, USA.
Introduction: Children and adolescents with Crohn's disease present unique challenges due to extensive disease at diagnosis and the effect of bowel inflammation on growth. Historical approaches with corticosteroids and immunomodulators are far less effective than early treatment with anti-TNF biologics.
Areas Covered: This review covers recent literature delineating the crucial role of early anti-TNF therapy in the treatment of moderate- to- severe Crohn's disease in children and adolescents.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!